Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
- PMID: 20511019
- PMCID: PMC7138079
- DOI: 10.1016/S0140-6736(10)60357-1
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
Abstract
Background: We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever.
Methods: A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV.
Findings: Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection.
Interpretation: This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections.
Funding: Defense Threat Reduction Agency.
Copyright 2010 Elsevier Ltd. All rights reserved.
Figures
Comment in
-
Are we any closer to combating Ebola infections?Lancet. 2010 May 29;375(9729):1850-2. doi: 10.1016/S0140-6736(10)60597-1. Lancet. 2010. PMID: 20511001 Free PMC article. No abstract available.
Similar articles
-
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.J Infect Dis. 2006 Jun 15;193(12):1650-7. doi: 10.1086/504267. Epub 2006 May 10. J Infect Dis. 2006. PMID: 16703508 Free PMC article.
-
Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.PLoS One. 2012;7(4):e36192. doi: 10.1371/journal.pone.0036192. Epub 2012 Apr 27. PLoS One. 2012. PMID: 22558378 Free PMC article.
-
Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. doi: 10.1093/infdis/jiw333. Epub 2016 Aug 28. J Infect Dis. 2016. PMID: 27571900 Free PMC article.
-
[Recent Advances in Vaccines and Drugs Against the Ebola Virus].Bing Du Xue Bao. 2015 May;31(3):287-92. Bing Du Xue Bao. 2015. PMID: 26470536 Review. Chinese.
-
Correlates of vaccine-induced protective immunity against Ebola virus disease.Semin Immunol. 2018 Oct;39:65-72. doi: 10.1016/j.smim.2018.07.003. Epub 2018 Jul 21. Semin Immunol. 2018. PMID: 30041831 Review.
Cited by
-
Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design.Acta Pharm Sin B. 2024 Feb;14(2):579-601. doi: 10.1016/j.apsb.2023.10.012. Epub 2023 Oct 20. Acta Pharm Sin B. 2024. PMID: 38322344 Free PMC article. Review.
-
Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges.J Biomed Sci. 2023 Oct 16;30(1):88. doi: 10.1186/s12929-023-00981-9. J Biomed Sci. 2023. PMID: 37845731 Free PMC article. Review.
-
Advances in modification and delivery of nucleic acid drugs.Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Aug 25;52(4):417-428. doi: 10.3724/zdxbyxb-2023-0130. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37643976 Free PMC article. Review. Chinese, English.
-
Molecular mechanism of palmitic acid and its derivatives in tumor progression.Front Oncol. 2023 Aug 9;13:1224125. doi: 10.3389/fonc.2023.1224125. eCollection 2023. Front Oncol. 2023. PMID: 37637038 Free PMC article. Review.
-
Innate immune regulations and various siRNA modalities.Drug Deliv Transl Res. 2023 Nov;13(11):2704-2718. doi: 10.1007/s13346-023-01361-4. Epub 2023 May 23. Drug Deliv Transl Res. 2023. PMID: 37219704 Free PMC article. Review.
References
-
- Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. Lippincott Williams and Wilkins; Philadelphia: 2006. pp. 1409–1448.
-
- Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993;29:215–240. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials